Acumen Pharmaceuticals, Inc. - Acumen Pharmaceuticals, Inc. 是医疗组中排名第四的公司[2] - Acumen Pharmaceuticals, Inc. 目前的Zacks排名为2（买入）[3] - Acumen Pharmaceuticals, Inc. 今年迄今为止的回报率为8.1%，高于医疗行业的平均回报率6.8%[4] - Acumen Pharmaceuticals, Inc. 属于医疗-生物医学和遗传学行业，排名第80[7] Ayr Wellness Inc. - Ayr Wellness Inc. 今年迄今为止的回报率为12%，表现优于医疗行业[5] - Ayr Wellness Inc. 目前的Zacks排名为2（买入）[6] - Ayr Wellness Inc. 属于医疗-产品行业，排名第89[8] - 投资者应继续关注Acumen Pharmaceuticals, Inc. 和Ayr Wellness Inc.，因为它们可能会保持良好的表现[9]

- Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 CHARLOTTESVILLE, Va., March 21, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the Company will present data from its Phase 1 INTERCEPT-AD study evaluating sabirnetug (ACU193) in early AD during an Emerging S ...

公司财务公告 - Acumen Pharmaceuticals, Inc.宣布将于2024年3月26日公布2023年第四季度和年度财务结果[1] - 公司将在东部时间上午8:00举行电话会议和现场音频网络研讨会，提供业务和财务更新[1] 参与方式 - 参与现场电话会议，请使用提供的链接进行注册，并至少提前一天注册[2] 网络研讨会信息 - 网络研讨会音频将在公司网站的投资者部分提供至少30天的存档版本[3] 公司信息 - Acumen Pharmaceuticals, Inc.总部位于弗吉尼亚州夏洛茨维尔，还在印第安纳州印第安纳波利斯和马萨诸塞州牛顿设有额外办公室[4]

CHARLOTTESVILLE, Va., March 19, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report fourth quarter and year-end 2023 financial results on Tuesday, March 26, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a ...

- Cerebrospinal fluid (CSF) biomarker results are highly supportive of sabirnetug's downstream pharmacological effects in the brain in early AD - Poster presentation showcases method used to develop a first-of-its-kind assay to assess sabirnetug's binding to amyloid beta oligomers (AβOs) in Alzheimer's disease - Company on track to initiate Phase 2 trial evaluating sabirnetug in the first half of 2024 and Phase 1 subcutaneous study in mid-2024 CHARLOTTESVILLE, Va., March 08, 2024 (GLOBE NEWSWIRE) -- Acumen ...

公司表现 - ABOS目前的Zacks Rank为2（买入），显示出公司具有优异的特性，有望在未来1至3个月内表现优于市场[3] - ABOS今年迄今为止的股价上涨了8.6%，高于医疗行业平均水平7.1%的表现[5] - ABOS所属的医疗-生物医学和遗传学行业今年迄今为止的平均涨幅为3%，ABOS在该行业表现更好[9]

CHARLOTTESVILLE, Va., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today the appointment of James Doherty, Ph.D., as President and Chief Development Officer, effective February 1, 2024, reporting to Daniel O'Connell, Chief Executive Officer. Dr. Doherty's responsibilities will include oversight of clin ...

As investors, we are often looking to diversify our portfolios. Especially with the wild AI craze in the past year, many investors already hold positions in AI or other technology companies. Adding a variety of stocks from different sectors in your portfolio can help reduce risk. It lessens your dependence on returns in one sector. Diversification with the top healthcare stocks to buy can help spread out your risk in case any one sector collapses. Although healthcare stocks aren’t discussed as much right no ...

Aging stocks (or longevity stocks) are drawing attention from investors for obvious reasons. The Baby Boomer generation is now almost fully retired, and Gen X is right on its heels. It is a profitable trend that’s not going away anytime soon. There are many ways to invest in an aging population. An obvious choice is healthcare stocks. The advancements in medical technology allow individuals to enjoy a better quality of life for much longer. Of course, as many Gen X and Millennial children can attest to, tha ...

公司背景 - Acumen Pharmaceuticals, Inc. 是一家位于弗吉尼亚州夏洛茨维尔的临床阶段生物制药公司，致力于开发针对毒性可溶性淀粉样蛋白β寡聚体的新型治疗药物，用于治疗阿尔茨海默病[1] - 公司的科学创始人在AβOs研究方面有着开创性的贡献，越来越多的证据表明AβOs是阿尔茨海默病病理的早期和持续触发因素[2] 产品研发 - Acumen Pharmaceuticals, Inc. 目前专注于推进其研究产品候选ACU193，这是一种选择性靶向毒性可溶性AβOs的人源单克隆抗体，该产品在早期阿尔茨海默病患者中的INTERCEPT-AD阶段1临床试验中取得了积极的头条结果[2]